This year, two important new regulations will be impacting research with human subjects: the EU’s General Data Protection Regulation (GDPR), which kicks in May 2018, and the USA’s updated Common Rule, called the Final Rule, is in effect from Jan 2018. Both changes relate to protecting individuals’ private information and will affect researchers using behavioral data in terms of data collection, access, use, applications for ethics committee (IRB) approvals/exemptions, collaborations within the same country/region and beyond, and collaborations with industry.
Both GDPR and the final rule try to modernize what today constitutes “private data” and data subjects’ rights and balance it against “free flow of information between EU countries” (GDPR) or . However, the GDPR’s approach is much more strongly in favor of protecting private data
Here are a few points to note about GDPR:
- “Personal data” (GDPR) or “private information” (final rule) is very broadly defined and includes data on physical, physiological or behavioral characteristics of a person “which allow or confirm the unique identification of that natural person”.
- The GDPR affects any organization within the EU as well as “external organizations that are trading within the EU”. It applies to personal data on any person, not just EU citizens/residents.
- The GDPR distinguishes between “data controller” (the entity who has the data, in the eyes of the data subjects, e.g. a hospital) and “data processor” (the entity who operates on the data). Both entities are bound and liable by GDPR.
- GDPR distinguishes between “data processing” (any operation related to the data including storage, structuring, record deletion, transfer) and “profiling” (automated processing of personal data to “evaluate personal aspects relating to a natural person”.
- The Final Rule now offers an option of relying on broad consent obtained for future research as an alternative to seeking IRB approval to waive the consent requirement.
- Domestic collaborations within the US now require a single institutional review board (IRB) approval (for the portion of the research that takes place within the US) – effective 2021.
The Final Rule tries to lower burden for low-risk research. One attempt is new “exemption” categories for secondary research use of identifiable private information (i.e. re-using
- The identifiable private information is publicly available;
- The information is recorded by the investigator in such a way that the identity of subjects cannot readily be ascertained, and the investigator does not contact subjects or try to re-identify subjects;
- The secondary research activity is regulated under HIPAA; or
- The secondary research activity is conducted by or on behalf of a federal entity and involves the use of federally generated non-research information provided that the original collection was subject to specific federal privacy protections and continues to be protected.